Search Results - "Eskazan, Ahmet"

Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted by Eşkazan, Ahmet Emre

Get full text

Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate by Eşkazan, Ahmet Emre

Get full text

Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic by Eşkazan, Ahmet Emre

Get full text

Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia? by Eskazan, Ahmet Emre

Get full text

Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest? by Eşkazan, Ahmet Emre

Get full text

Platelet count threshold for lumbar puncture: Does one size really fit all? by Eşkazan, Ahmet Emre

Get full text

A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death-Are they synonymous? by Eşkazan, Ahmet Emre

Get more information

Evolving treatment strategies in CML – moving from early and deep molecular responses to TKI discontinuation and treatment‐free remission: is there a need for longer‐term trial outcomes? by Eşkazan, Ahmet Emre

Get full text

What is the best treatment approach for sporadic late‐onset nemaline myopathy associated with “monoclonal gammopathy of neurological significance”? by Eşkazan, Ahmet Emre, Gündüz, Ayşegül

Get full text

Dasatinib‐induced pulmonary arterial hypertension by Özgür Yurttaş, Nurgül, Eşkazan, Ahmet Emre

“…Drug‐induced (group 1) pulmonary hypertension (PH) is an important subgroup of PH involving dasatinib as a likely related agent, which is a second‐generation…”
Get full text

Novel therapeutic approaches in chronic myeloid leukemia by Özgür Yurttaş, Nurgül, Eşkazan, Ahmet Emre

“…•TKIs have revolutionized the management of CML.•Some CML patients may still need additional treatment options other than TKIs.•These treatment options may…”
Get full text

Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) by Patır, Püsem, Önkibar, Nurtaç, Subari, Sedef, Eşkazan, Ahmet Emre

Get full text

Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting by Yılmaz, Reyhan, Eşkazan, Ahmet Emre

Get full text

Asciminib in chronic myeloid leukemia: many questions still remain to be answered by Eşkazan, Ahmet Emre

Get full text

Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities by Narlı Özdemir, Zehra, Kılıçaslan, Necati Alp, Yılmaz, Musa, Eşkazan, Ahmet Emre

“…Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to…”
Get full text

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions by Nuhoğlu Kantarcı, Eda, Eşkazan, Ahmet Emre

“…Acute myeloid leukemia (AML) is defined as a highly progressive heterogeneous hematologic malignancy characterized by loss of differentiation with uncontrolled…”
Get full text

Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient by Nuhoğlu Kantarcı, Eda, Tolgay, Ece, Eşkazan, Ahmet Emre

“…In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic‐phase chronic myeloid leukemia, this editorial focuses on…”
Get full text

Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review by Baysal, Mehmet, Bayrak, Meltem, Eşkazan, Ahmet Emre

“…Thromboembolic events in myeloproliferative neoplasms (MPNs) are one of the most important causes of mortality and morbidity, in which vitamin K antagonists…”
Get more information

Chronic Myeloid Leukemia in Renal Transplantation Patients in the Era of Tyrosine Kinase Inhibitors: A Case Report and Review of the Literature by Murt, Ahmet, Bayram, Batuhan, Yılmaz, Umut, Seyahi, Nurhan, Eşkazan, Ahmet Emre

“…Lifelong immunosuppression, cytotoxic effects of some immunosuppressive drugs, and opportunistic oncogenic viruses increase malignancy risks in solid organ…”
Get more information

Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults by Mersin, Sinan, Gülük, Fatih, Gülcan, Emirhan, Eşkazan, Ahmet Emre

“…Chronic myeloid leukemia (CML) is more common in older adults, but nearly 15-20% of the patients is between 15 and 39 years of age. In this age group, patients…”
Get more information